CL2021002137A1 - Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. - Google Patents
Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.Info
- Publication number
- CL2021002137A1 CL2021002137A1 CL2021002137A CL2021002137A CL2021002137A1 CL 2021002137 A1 CL2021002137 A1 CL 2021002137A1 CL 2021002137 A CL2021002137 A CL 2021002137A CL 2021002137 A CL2021002137 A CL 2021002137A CL 2021002137 A1 CL2021002137 A1 CL 2021002137A1
- Authority
- CL
- Chile
- Prior art keywords
- thioene
- pyridin
- familial dysautonomia
- amine compounds
- treat familial
- Prior art date
Links
- 208000001730 Familial dysautonomia Diseases 0.000 title abstract 2
- 201000001638 Riley-Day syndrome Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805283P | 2019-02-13 | 2019-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002137A1 true CL2021002137A1 (es) | 2022-02-25 |
Family
ID=69960696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002137A CL2021002137A1 (es) | 2019-02-13 | 2021-08-12 | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12384797B2 (https=) |
| EP (1) | EP3924049A1 (https=) |
| JP (1) | JP7587511B2 (https=) |
| KR (1) | KR102907028B1 (https=) |
| CN (1) | CN113795304A (https=) |
| AU (1) | AU2020222881C1 (https=) |
| BR (1) | BR112021015853A2 (https=) |
| CA (1) | CA3129067A1 (https=) |
| CL (1) | CL2021002137A1 (https=) |
| CO (1) | CO2021010598A2 (https=) |
| EA (1) | EA202192170A1 (https=) |
| IL (1) | IL285399B2 (https=) |
| MX (1) | MX2021009667A (https=) |
| PE (1) | PE20220139A1 (https=) |
| SG (1) | SG11202108519TA (https=) |
| UA (1) | UA129890C2 (https=) |
| WO (1) | WO2020167628A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| CN115209955A (zh) * | 2019-12-12 | 2022-10-18 | Ptc医疗公司 | 治疗家族性自主神经功能障碍的化合物 |
| BR112022023025A2 (pt) | 2020-05-13 | 2023-03-28 | Chdi Foundation Inc | Moduladores de htt para tratar doença de huntington |
| EP4277626A4 (en) * | 2021-01-14 | 2024-12-11 | Georgetown University | USP13 INHIBITORS AND METHODS OF USE THEREOF |
| CN112920053B (zh) * | 2021-02-01 | 2022-07-01 | 暨明医药科技（苏州）有限公司 | 一种手性α-甲基芳乙胺的制备方法 |
| EP4288059A4 (en) * | 2021-02-05 | 2025-01-08 | PTC Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| US20240041886A1 (en) * | 2021-02-05 | 2024-02-08 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| US20240051968A1 (en) * | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| TW202313623A (zh) | 2021-06-03 | 2023-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其藥用用途 |
| EP4398987A4 (en) * | 2021-09-07 | 2025-07-09 | Ptc Therapeutics Inc | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| US20250127789A1 (en) * | 2021-11-04 | 2025-04-24 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| WO2023212237A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| US20260001889A1 (en) | 2022-05-12 | 2026-01-01 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| MA71255A (fr) * | 2022-06-22 | 2025-04-30 | Ptc Therapeutics, Inc. | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
| WO2024036143A2 (en) * | 2022-08-09 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| JP3126541B2 (ja) | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| NZ335823A (en) | 1997-04-22 | 2001-06-29 | Neurocrine Biosciences Inc | Thiophenopyridines, preparation as CRF receptor antagonists |
| EP1028964A1 (en) | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| CL2003002287A1 (es) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| WO2004065392A1 (en) | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| CA2540681C (en) | 2003-10-03 | 2014-08-12 | The General Hospital Corporation | Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders |
| JP2009007341A (ja) | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
| BRPI0912245A2 (pt) | 2008-03-05 | 2019-09-24 | Takeda Pharmaceuticals Co | composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| WO2012012656A2 (en) | 2010-07-21 | 2012-01-26 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
| EP2611812A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP2867236B1 (en) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014124458A1 (en) | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
| CN105339371A (zh) | 2013-03-07 | 2016-02-17 | 葛兰素史密斯克莱有限责任公司 | 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物 |
| CN110218727A (zh) | 2013-03-14 | 2019-09-10 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| US9879014B2 (en) * | 2013-07-12 | 2018-01-30 | Kyoto University | Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease |
| RU2692634C2 (ru) | 2013-10-07 | 2019-06-25 | Академиш Зикенхойс Лейден Х.О.Д.Н. Люмк | Направляемое антисмысловым олигонуклеотидом удаление сайтов протеолитического расщепления, мутации hchwa-d и увеличенного числа тринуклеотидных повторов |
| KR102390370B1 (ko) | 2014-02-12 | 2022-04-26 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| CA2973949C (en) | 2015-01-16 | 2023-07-11 | The General Hospital Corporation | Compounds for improving mrna splicing |
| ES2865330T3 (es) | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| EP4285912A3 (en) | 2015-09-25 | 2024-07-10 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| EP3494229B1 (en) | 2016-08-03 | 2023-10-25 | Meiragtx UK II Limited | High throughput cell-based screening for aptamers |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018151326A1 (ja) | 2017-02-20 | 2018-08-23 | 国立大学法人京都大学 | スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法 |
| US10538571B2 (en) | 2017-11-27 | 2020-01-21 | Coda Biotherapeutics, Inc. | Compositions and methods for neurological diseases |
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| CN109819066A (zh) | 2019-01-31 | 2019-05-28 | 平安科技（深圳）有限公司 | 一种基于地理位置的智能解析域名方法及装置 |
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| EP3929185A4 (en) | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| CN113950529A (zh) | 2019-06-06 | 2022-01-18 | 豪夫迈·罗氏有限公司 | 靶向atxn3的反义寡核苷酸 |
| US11798161B2 (en) | 2019-11-26 | 2023-10-24 | Koh Young Technology Inc. | Method and apparatus for determining mid-sagittal plane in magnetic resonance images |
| CN115209955A (zh) | 2019-12-12 | 2022-10-18 | Ptc医疗公司 | 治疗家族性自主神经功能障碍的化合物 |
| US20230117831A1 (en) | 2020-01-08 | 2023-04-20 | The Broad Institute, Inc. | Multi-functional chimeric molecules |
| US20240051968A1 (en) | 2021-02-05 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| EP4288059A4 (en) | 2021-02-05 | 2025-01-08 | PTC Therapeutics, Inc. | Compounds for treating spinocerebellar ataxia type 3 |
| EP4288441A4 (en) | 2021-02-05 | 2024-12-11 | PTC Therapeutics, Inc. | Methods for treating spinocerebellar ataxia type 3 |
| JP2024513566A (ja) | 2021-04-09 | 2024-03-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | 標的基質の選択的修飾のための二官能性分子 |
| EP4398987A4 (en) | 2021-09-07 | 2025-07-09 | Ptc Therapeutics Inc | METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES |
| CN118251225A (zh) | 2021-09-07 | 2024-06-25 | Ptc医疗公司 | 治疗神经退行性疾病的方法 |
| MX2024002887A (es) | 2021-09-07 | 2024-05-28 | Ptc Therapeutics Inc | Metodos para tratar enfermedades neurodegenerativas. |
| US20250127789A1 (en) | 2021-11-04 | 2025-04-24 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| MA71255A (fr) | 2022-06-22 | 2025-04-30 | Ptc Therapeutics, Inc. | Composés pour le traitement de l'ataxie spinocérébelleuse de type 3 |
-
2020
- 2020-02-10 SG SG11202108519TA patent/SG11202108519TA/en unknown
- 2020-02-10 BR BR112021015853-7A patent/BR112021015853A2/pt unknown
- 2020-02-10 WO PCT/US2020/017430 patent/WO2020167628A1/en not_active Ceased
- 2020-02-10 KR KR1020217028864A patent/KR102907028B1/ko active Active
- 2020-02-10 MX MX2021009667A patent/MX2021009667A/es unknown
- 2020-02-10 UA UAA202105103A patent/UA129890C2/uk unknown
- 2020-02-10 IL IL285399A patent/IL285399B2/en unknown
- 2020-02-10 US US17/430,511 patent/US12384797B2/en active Active
- 2020-02-10 EA EA202192170A patent/EA202192170A1/ru unknown
- 2020-02-10 EP EP20714017.9A patent/EP3924049A1/en active Pending
- 2020-02-10 PE PE2021001329A patent/PE20220139A1/es unknown
- 2020-02-10 CA CA3129067A patent/CA3129067A1/en active Pending
- 2020-02-10 CN CN202080028449.2A patent/CN113795304A/zh active Pending
- 2020-02-10 AU AU2020222881A patent/AU2020222881C1/en active Active
- 2020-02-10 JP JP2021547446A patent/JP7587511B2/ja active Active
-
2021
- 2021-08-12 CL CL2021002137A patent/CL2021002137A1/es unknown
- 2021-08-12 CO CONC2021/0010598A patent/CO2021010598A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021015853A2 (pt) | 2021-10-05 |
| PE20220139A1 (es) | 2022-01-27 |
| UA129890C2 (uk) | 2025-09-03 |
| IL285399B2 (en) | 2025-06-01 |
| IL285399B1 (en) | 2025-02-01 |
| AU2020222881B2 (en) | 2025-07-10 |
| WO2020167628A1 (en) | 2020-08-20 |
| KR20210137040A (ko) | 2021-11-17 |
| JP7587511B2 (ja) | 2024-11-20 |
| US12384797B2 (en) | 2025-08-12 |
| AU2020222881C1 (en) | 2026-01-22 |
| EP3924049A1 (en) | 2021-12-22 |
| KR102907028B1 (ko) | 2026-01-05 |
| US20220135586A1 (en) | 2022-05-05 |
| CO2021010598A2 (es) | 2021-08-30 |
| AU2020222881A1 (en) | 2021-09-09 |
| CA3129067A1 (en) | 2020-08-20 |
| EA202192170A1 (ru) | 2021-11-15 |
| IL285399A (en) | 2021-09-30 |
| SG11202108519TA (en) | 2021-09-29 |
| JP2022520822A (ja) | 2022-04-01 |
| MX2021009667A (es) | 2021-12-10 |
| CN113795304A (zh) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021010598A2 (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar | |
| ECSP21085481A (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| CL2022003434A1 (es) | Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378) | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CR20240567A (es) | Compuestos para tratar la ataxia espinocerebelosa tipo 3. | |
| CL2022001523A1 (es) | Compuestos para tratar la disautonomía familiar | |
| CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
| CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CO2018005370A2 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| ECSP19082194A (es) | Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas | |
| BRPI0408026A (pt) | Quinazolinas úteis como moduladores de canais de ìon | |
| MX389545B (es) | Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias. | |
| ECSP056020A (es) | Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion | |
| ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
| CL2024000250A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| CR20140216A (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
| CL2009000275A1 (es) | Compuestos derivados de furo [3,2-c]piridina y tieno [3,2-c] piridina; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CO2019003894A2 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX2020004179A (es) | Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso. | |
| NI200700311A (es) | Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3 | |
| CR20190429A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA-DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| MX2019009288A (es) | Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, metodos de fabricacion, y metodos de utilizacion. | |
| CR20220345A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos |